AMAG Pharma: USPTO Extends Patent Term For Ferumoxytol By 1,209 Days

(RTTNews) - AMAG Pharmaceuticals Inc. (AMAG) announced the United States Patent and Trademark Office (USPTO) has extended the term of the company's U.S. Patent directed to reduced polysaccharide iron oxide complexes, including ferumoxytol. With the extension, the '498 patent will now expire June 30, 2023.

"This patent extension for ferumoxytol further lengthens our intellectual property protection and enhances the long-term value of a product that generated 28 percent revenue growth in the U.S. in 2013 for our company," said William Heiden, CEO of AMAG.

In the U.S., Feraheme (ferumoxytol) Injection for Intravenous use is indicated for the treatment of iron deficiency anemia in adult patients who have failed oral iron therapy. Feraheme received marketing approval from the FDA on June 30, 2009 for the treatment of IDA in adult chronic kidney disease patients and was commercially launched by AMAG in the U.S. shortly thereafter. Ferumoxytol is protected in the U.S. by five issued patents.